Walter M. Stadler

Advantages of genomic complexity: bioinformatics opportunities in microRNA cancer signatures

Yves A. Lussier, James L. Chen, Walter M. Stadler, 2011, J. Am. Medical Informatics Assoc..

Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence

Yves A. Lussier, Jianrong Li, James L. Chen, 2011, J. Am. Medical Informatics Assoc..

Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents

Lawrence D. True, Susan Groshen, Walter M. Stadler, 2010, Clinical Cancer Research.

Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial

Walter M. Stadler, Christopher R. Heery, James L. Gulley, 2016, Oncotarget.

Patient-Provider Communications About Pharmacogenomic Results Increase Patient Recall of Medication Changes

Walter M. Stadler, David O. Meltzer, Mark J. Ratain, 2018, The Pharmacogenomics Journal.

MR imaging-guided focal laser ablation for prostate cancer: phase I trial.

Aytekin Oto, Walter M. Stadler, Marko K. Ivancevic, 2013, Radiology.

Effect of the addition of temsirolimus to cetuximab in cetuximab-resistant head and neck cancers: Results of the randomized PII MAESTRO study.

Yves A. Lussier, Walter M. Stadler, Apoorva Chawla, 2014 .